Brian Cosgrove

Principal Scientist @tunetx_news. Alum of the Gersbach Lab @DukeU and the Mauck Lab @Penn BE PhD. Excited about Epigenetics, coffee, and tech.

[Hao Yin @HaoYin20]

Mechanosensitive Enhancer

Fibroblasts in response to Matrix Stiffness 50 vs 1 kPa

👉Bulk RNAseq
👉On-plate Omni ATACseq (NO detachment required🤠) + TOBIAS transcription factor footprinting analysis▶️Intronic mechanoenhancer for BMF (Anoikis-related) on soft matrix
👉HiCAR
👉CRSIPRi dCAS9-KRAB epigenomic editing for enhancer locus screening
👉Single-cell CRISPRi

21.8% putative mechanoenhancers "skipped 5 or more genes"😎

@itsbcos @cgersbach @ScienceMagazine 2025
https://t.co/mQRBTWff2E

[Brian Cosgrove @itsbcos]

My postdoc work is now published in #Science! In this work we found that the non-coding genome can harbor mechanically-sensitive genomic enhancers (“mechanoenhancers”) that governing the transcriptional and functional responses to ECM stiffness. https://t.co/SETG9b4fef

[Brian Cosgrove @itsbcos]

@BurdickLab @BioFrontiers @CUEngineering @pennbioeng Congrats Jason!

[CRISPR Medicine @CrisprMedicine]

𝐓𝐮𝐧𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬: 𝐂𝐚𝐧 𝐄𝐩𝐢𝐠𝐞𝐧𝐨𝐦𝐞 𝐄𝐝𝐢𝐭𝐢𝐧𝐠 𝐂𝐮𝐫𝐞 𝐇𝐞𝐩𝐚𝐭𝐢𝐭𝐢𝐬 𝐁?

🦠 By targeting a highly conserved master controller gene, Tune Therapeutics' lead candidate TUNE-401 can epigenetically silence all forms of the hepatitis B virus, providing hope for a functional cure.

📰 Read more in our latest interview with Brian Cosgrove: https://t.co/Re5qjxiDHW

🖋 Interview by: Rebecca Roberts

[nature @Nature]

CRISPR 2.0: a new wave of gene editors heads for clinical trials https://t.co/Fp8iLXWfzE

[Brian Cosgrove @itsbcos]

Glad to get the chance to talk w/ @GrinsteinJ & @GENbio about our work at Tune to develop epi-silencing tools to treat patients with chronic Hepatitis B infection -Jonathan does a great job capturing how we take advantage of HBV’s unique Franken-chromatin! https://t.co/gTCNyRw1JS

[Tune Therapeutics @tunetx_news]

The excitement is building for #HepDART2023 next week.

Brian Cosgrove, Principal Scientist at #TuneTx will be sharing exciting, new data from our #HBV program in his presentation, "Epigenetic editing for the treatment of HBV" on Dec 5 at 11:10 AM MST.

https://t.co/5IPPFgsxiP

[Tune Therapeutics @tunetx_news]

The Tune HBV program was unveiled by Dr. Ed Gane, Professor of Medicine at the University of Auckland and world-renowned authority on Hepatitis B Virus (HBV) at the @AASLDtweets conference in Boston on November 11th.

Read the full press release: https://t.co/70HqDJXvCu

#TLM23

[Brian Cosgrove @itsbcos]

@BurdickLab @ClaudiaLoebel Congrats @ClaudiaLoebel :)

[Brian Cosgrove @itsbcos]

@soniab742 @DukeU Congrats! Duke is lucky to have you!

[Brian Cosgrove @itsbcos]

@YSPTSPS Happy to give my 2c. Lots of great folks in that area at Penn - could always talk to someone from @MauckLab @DymentLabPenn @HughesLabPenn @jboerckel @Penn_PCMD etc.

[Brian Cosgrove @itsbcos]

@GerechtLab @MauckLab @BurdickLab Thanks for the read :)

[Brian Cosgrove @itsbcos]

@stephaniegcone @udbme @UDengineering Congrats!!

[Brian Cosgrove @itsbcos]

What a horrible, horrible day in American history.

[Brian Cosgrove @itsbcos]

@lara_silverman Im so sorry to hear about these awful experiences Lara-- glad that you had the strength to bring these issues to light & hope that this helps contribute to biotech organizations doing more to police these toxic behaviors and keep this from happening to others :(.

[Lammerding Lab @LammerdingLab]

More fun with lattice light sheet microscopy, courtesy of the AIC @HHMIJanelia. Imaging tumor cells with fluorescently labeled histones and actin dividing in a dense collagen matrix.

[Brian Cosgrove @itsbcos]

@AL_Mattei Wow - what a wonderful review. Crazy detailed and well-organizied!

[Brian Cosgrove @itsbcos]

@spence_sz3 @NSF @PennStateBME Congrats Spence!

[Brian Cosgrove @itsbcos]

@DrKlapperich Wondering how that balance changes at a symptomatic testing site

[Brian Cosgrove @itsbcos]

@DrKlapperich Aren’t these tests answering two slightly different questions though? This is something that @michaelmina_lab has been talking about - A rapid test is answering the question of “am I infectious now?” whereas PCR can stay positive for a long time after you’ve been infectious.